NCT06598124

Brief Summary

We are aiming to assess the effects of low lactose milk containing galactooligosaccharides (GOS) on digestive response in healthy Chinese adults in comparison with a matching milk containing lactose.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for not_applicable healthy

Timeline
Completed

Started Aug 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 15, 2024

Completed
5 days until next milestone

Study Start

First participant enrolled

August 20, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 21, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

8 months

First QC Date

August 15, 2024

Last Update Submit

November 21, 2025

Conditions

Keywords

LactoseGOSDigestive responseGut comfort

Outcome Measures

Primary Outcomes (2)

  • Small bowel water content

    Small bowel water content measured via MRI and calculated using the trapezoidal rule (mL\*min) at 45 minutes of interval

    0-315 minutes after investigational product (IP) or comparator product (CP) intake

  • Gut motility

    Maximum gut motility after product consumption (arbitrary unit) assessed via MRI performed every 45 min

    0-315 minutes after IP or CP intake

Secondary Outcomes (11)

  • Gastric emptying

    0-315 minutes after IP or CP intake

  • Retention rate of gastric content volumes

    0-315 minutes after IP or CP intake

  • Oro-caecal transit

    0-315 minutes after IP or CP intake

  • H2 levels

    0-315 minutes after IP or CP intake

  • Colonic volume

    0-315 minutes after IP or CP intake

  • +6 more secondary outcomes

Other Outcomes (1)

  • Appetite

    0-315 minutes after IP or CP intake

Study Arms (2)

Arm 1

OTHER

Visit 1: Comparator Product; Visit 2: Investigational Product

Other: Investigational Product (IP)Other: Comparator Product (CP)

Arm 2

OTHER

Visit 1: Investigational Product; Visit 2: Comparator Product

Other: Investigational Product (IP)Other: Comparator Product (CP)

Interventions

1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.

Arm 1Arm 2

1 single dose of CP consisting in 400 mL of milk with lactose

Arm 1Arm 2

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Participants declare that they are of Chinese ethnicity as well as both of their biological parents
  • Women and men aged between 18 and 60 years
  • Body mass index (BMI ≥ 18.5 \& \<30 kg/m2)
  • Healthy: no medical conditions or previous gastrointestinal surgery which might affect study measurements (as declared by the participant)
  • Able to understand and to sign written informed consent prior to study entry
  • Informed consent signed
  • Meets all the criteria for MRI Scan
  • Can read and speak English

You may not qualify if:

  • Medically diagnosed milk allergy
  • Subjects not willing and/or not able to comply with scheduled visits and the requirements of the study protocol
  • Diagnosed with any gastrointestinal disorders
  • History of claustrophobia
  • Pregnant (defined by pregnancy test) or breast feeding
  • History or current psychiatric illness
  • History or current neurological condition (e.g. epilepsy)
  • Consumption of \> 21 alcoholic drinks in a typical week (one serving is 0.4 dl of spirits, 1 dl of wine, or 3 dl of beer as declared by participant)
  • Currently smoking (as declared by participant)
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
  • Antibiotic use within the 4 weeks preceding the intervention
  • Probiotic \& prebiotics use within the 2 weeks preceding the intervention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nottingham

Nottingham, United Kingdom

Location

Study Officials

  • Irma Silva Zolezzi

    Societé des Produits Nestlé SA

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Single coding
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Double-blind, randomized, 2x2 cross-over study
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2024

First Posted

September 19, 2024

Study Start

August 20, 2024

Primary Completion

April 21, 2025

Study Completion

June 30, 2025

Last Updated

November 24, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations